Emerson Electric Co. (EMR)

FairStock Score: 52/100 — MIXED

Key Financials

Strengths

• Diversified industrial portfolio across Final Control, Automation, and Measurement segments serving multiple end markets
• Solid free cash flow generation of $2.9B demonstrates operational cash conversion capability
• 13.92% net margin in latest quarter shows operational profitability and pricing power in select segments
• Established 71,000-person workforce suggests scale and operational integration across global markets

Concerns

• Valuation catastrophically detached from intrinsic value—P/E of 31.41 versus Graham fair value of $29.61 indicates 376% overvaluation
• Anemic return metrics (ROE 9.65%, ROCE 6.61%) fail to justify premium multiple or cost of capital
• Deteriorating financial quality with Piotroski F-Score of only 5/9 signals weakening fundamentals
• Extremely high EV/EBITDA of 73.22 and minimal FCF yield of 0.8% create negligible margin of safety

AI Analysis

I'm examining Emerson Electric with considerable skepticism. While the company operates in attractive industrial niches with 71,000 employees generating $4.3B quarterly revenue, the valuation presents a significant obstacle to sound investment. At $141.12 per share, we're looking at a P/E of 31.41—well above historical averages for an industrial company—and the Graham Number suggests fair value around $29.61, implying a negative margin of safety of -376%. This is precisely the type of premium pricing that destroys long-term returns. The fundamentals reveal mediocre capital efficiency: ROE of 9.65% and ROCE of 6.61% are uninspiring for a $79.4B market capitalization. The company generates solid free cash flow of $2.9B, yet that represents only 0.8% FCF yield—inadequate compensation for equity holders at current prices. What particularly concerns me is the Piotroski F-Score of 5/9, suggesting deteriorating financial quality, combined with an alarming EV/EBITDA ratio of 73.22. The debt-to-equity of 0.69 is manageable, but not reassuring. EMR operates in reasonable industrial segments—control systems, measurement equipment, automation—but I see no durable competitive moat warranting such valuation multiples. This is neither a business of exceptional quality nor one priced for margin of safety. I pass.

Bull Case

EMR occupies essential positions in industrial automation and process control with sticky customer relationships. Industrial spending cycles may strengthen post-2025, potentially driving margin expansion and justifying elevated multiples if execution improves and debt decreases.

Bear Case

The company is priced for perfection in a market prone to cyclicality. Modest ROCE and ROE suggest capital is not deployed with superior efficiency, and any economic downturn will expose the valuation premium as completely unjustified.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer